Document is current
Any future updates will be listed below
-
Authors
Hirayama, Masaya
Ohyama, Yukako
Tsuji, Yudai
Enomoto, Tetsuro
Hasegawa, Midori
Tsuboi, Naotake
Novak, Jan
Takahashi, Kazuo https://orcid.org/0000-0002-5774-4620
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science London (20K22915)
Japan Society for the Promotion of Science London (22K16230)
Japan Society for the Promotion of Science London (22K08366)
Aichi Kidney Foundation
Foundation for the National Institutes of Health (DK078244)
Foundation for the National Institutes of Health (DK082753)
UAB research-acceleration funds (AI149431)
- License Information
-
More Information
Article History
Received: 14 May 2024
Accepted: 7 March 2025
First Online: 7 April 2025
Declarations
:
: JN is a co-inventor on US patent application 14/318,082 (assigned to the UAB Research Foundation) and a co-founder, co-owner, and consultant for Reliant Glycosciences, LLC, and received honoraria from Travere, Inc, Calliditas, and Vera Therapeutics. NT received honorarium from AstraZeneca K. K. and Kissei Pharmaceutical Co., Ltd.; research funds from Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi Co., Ltd., and Zenyaku Holdings Co., Ltd.; donations from Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., and Torii Pharmaceutical Co., Ltd.; and travel fee from Sanofi Co., Ltd. The other authors declare no competing interests.
: All experimental protocols were approved by the Institutional Review Board (IRB) of Fujita Health University (approval number: HM22-140). Informed consent was obtained from all participants. All experimental methods were performed in accordance with the relevant guidelines and regulations.
